(S)-1,4-benzodioxane-2-carboxaldehyde | 115563-62-7

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯并二恶烷
• 英文名称: (S)-1,4-benzodioxane-2-carboxaldehyde
• 英文别名: (S)-2,3-Dihydrobenzo[b][1,4]dioxine-2-carbaldehyde；(3S)-2,3-dihydro-1,4-benzodioxine-3-carbaldehyde
• CAS: 115563-62-7
• 化学式: C₉H₈O₃
• 分子量: 164.161
• InChiKey: TVBNTFVSONEKOU-SSDOTTSWSA-N

物化性质

• 沸点：
  265.9±39.0 °C(Predicted)
• 密度：
  1.314±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.3
• 重原子数：
  12
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.22
• 拓扑面积：
  35.5
• 氢给体数：
  0
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  (S)-1,4-benzodioxane-2-carboxaldehyde 在 sodium tetrahydroborate 、 sodium meta bi sulfate 作用下， 以 甲醇 、 乙醇 、 水 、 乙酸乙酯 为溶剂， 反应 3.0h， 生成 (R)-2-(羟基甲基)-1,4-苯并二噁烷
  参考文献：
  名称：

  From 2-Aminomethyl-1,4-benzodioxane Enantiomers to Unichiral 2-Cyano- and 2-Carbonyl-Substituted Benzodioxanes via Dichloroamine

  摘要：

  2-Substituted 1,4-benzodioxanes, such as 2-cyano-, 2-methoxycarbonyl-, 2-aminocarbonyl-, and 2-formyl-1,4-benzodioxane, are key synthons that for the most part are never described as enantiomers or are inadequately characterized for enantiomeric purity. They were prepared by quantitative N,N-dichlorination of (R)- and (S)-2-aminomethyl-1,4-benzodioxane and successive functional group conversions in high yields without any racemization of the stereogenic benzodioxane C(2).

  DOI：

  10.1021/jo500964y
• 作为产物：
  描述：

  (R)-2-N,N-dichloroaminomethyl-1,4-benzodioxane 在 二异丁基氢化铝 、 1,8-二氮杂双环[5.4.0]十一碳-7-烯 作用下， 以 二氯甲烷 、 甲苯 为溶剂， 反应 0.75h， 生成 (S)-1,4-benzodioxane-2-carboxaldehyde
  参考文献：
  名称：

  From 2-Aminomethyl-1,4-benzodioxane Enantiomers to Unichiral 2-Cyano- and 2-Carbonyl-Substituted Benzodioxanes via Dichloroamine

  摘要：

  2-Substituted 1,4-benzodioxanes, such as 2-cyano-, 2-methoxycarbonyl-, 2-aminocarbonyl-, and 2-formyl-1,4-benzodioxane, are key synthons that for the most part are never described as enantiomers or are inadequately characterized for enantiomeric purity. They were prepared by quantitative N,N-dichlorination of (R)- and (S)-2-aminomethyl-1,4-benzodioxane and successive functional group conversions in high yields without any racemization of the stereogenic benzodioxane C(2).

  DOI：

  10.1021/jo500964y

文献信息

• Alicyclic carboxylic acid derivatives of benzomorphans and related scaffolds, medicaments containing such compounds and their use
  申请人：Peters Stefan

  公开号：US20110269791A1

  公开（公告）日：2011-11-03

  The present invention relates to compounds defined by Formula (I), wherein the groups A, B, X, m, n and o are defined as in claim 1, possessing valuable pharmacological activity. Particularly the compounds are inhibitors of 11β-hydroxysteroid dehydrogenase (HSD) 1 and thus are suitable for treatment and prevention of diseases which can be influenced by inhibition of this enzyme, such as metabolic diseases, in particular diabetes type 2, obesity and dyslipidemia.

  本发明涉及由式（I）定义的化合物，其中A、B、X、m、n和o基团的定义如权利要求1中所述，具有有价值的药理活性。特别是这些化合物是11β-羟基类固醇脱氢酶（HSD）1的抑制剂，因此适用于治疗和预防可以受到该酶抑制影响的疾病，如代谢性疾病，特别是2型糖尿病、肥胖症和血脂异常。
• LIGANDS FOR MONOAMINE RECEPTORS AND TRANSPORTERS, AND METHODS OF USE THEREOF
  申请人：Aquila Brian M.

  公开号：US20090258901A1

  公开（公告）日：2009-10-15

  One aspect of the present invention relates to heterocyclic compounds. A second aspect of the present invention relates to the use of the heterocyclic compounds as ligands for various mammalian cellular receptors, including dopamine, serotonin, or norepinephrine transporters. The compounds of the present invention will find use in the treatment of numerous ailments, conditions and diseases which afflict mammals, including but not limited to addiction, anxiety, depression, sexual dysfunction, hypertension, migraine, Alzheimer's disease, obesity, emesis, psychosis, schizophrenia, Parkinson's disease, inflammatory pain, neuropathic pain, Lesche-Nyhane disease, Wilson's disease, and Tourette's syndrome. An additional aspect of the present invention relates to the synthesis of combinatorial libraries of the heterocyclic compounds, and the screening of those libraries for biological activity, e.g., in assays based on dopamine transporters.

  本发明的一个方面涉及杂环化合物。本发明的第二个方面涉及将杂环化合物用作各种哺乳动物细胞受体的配体，包括多巴胺、血清素或去甲肾上腺素转运体。本发明的化合物将用于治疗许多影响哺乳动物的疾病、状况和疾病，包括但不限于成瘾、焦虑、抑郁、性功能障碍、高血压、偏头痛、阿尔茨海默病、肥胖症、呕吐、精神病、精神分裂症、帕金森病、炎性疼痛、神经痛、Lesche-Nyhane病、威尔逊病和托瑞特综合症。本发明的另一个方面涉及合成杂环化合物的组合库，并对这些库进行生物活性筛选，例如基于多巴胺转运体的测定。
• Serotonergic properties of spiroxatrine enantiomers
  作者：Sham S. Nikam、Arnold R. Martin、David L. Nelson

  DOI：10.1021/jm00118a017

  日期：1988.10

  The neuroleptic drug spiperone (1) has proven very useful in the characterization of putative serotonin (5-hydroxytryptamine, 5-HT) receptors. Thus, 5-HT1 receptors have been divided into subtypes based on their affinities for 1: 5-HT1A sites have high affinity, while 5-HT1B sites have low affinity. However, the usefulness of 1 for the pharmacological characterization of 5-HT1A sites is limited because of its high affinity for 5-HT2 (as well as D2-dopaminergic) receptors. A close analogue of 1, (+/-)-spiroxatrine (2), has much higher affinity for 5-HT1A receptors and much lower affinity for 5-HT2 receptors. We report here the stereospecific synthesis of (R)-(+)- and (S)-(-)-spiroxatrine enantiomers and their evaluation at several 5-HT receptors and D2-dopaminergic and alpha 1-adrenergic receptors.
• US7816375B2
  申请人：——

  公开号：US7816375B2

  公开（公告）日：2010-10-19
• US8765780B2
  申请人：——

  公开号：US8765780B2

  公开（公告）日：2014-07-01